MedTrace Logo

A CT-based Radiomics Model to Predict Survival-graded Fibrosis in PDAC

NCT06267690 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 295

Last updated 2024-02-20

No results posted yet for this study

Summary

Tumor fibrosis plays an important role in chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC), however there remains a contradiction in the prognostic value of fibrosis. We aimed to investigate the relationship between tumor fibrosis and survival in patients with PDAC, classify patients into high- and low-fibrosis groups, and develop and validate a CT-based radiomics model to non-invasively predict fibrosis before treatment.

Conditions

Interventions

PROCEDURE

surgery

Patients with suspected pancreatic cancer who underwent contrast-enhanced CT and pathological examinations after the surgery.

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Shi-Ting Feng, MD · First Affiliated Hospital, Sun Yat-Sen University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-13
Primary Completion
2023-08-31
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06267690 on ClinicalTrials.gov